Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: ALXN
CUSIP: 01535110

Key Metrics:

Previous Close: $133.69
50 Day Moving Average: $130.81
200 Day Moving Average: $135.64
52-Week Range: $224,248,000.00 - $110.56
Trailing P/E Ratio: 319.65
Foreward P/E Ratio: 24.70
P/E Growth: 1.50
Market Cap: $28.53B
Outstanding Shares: 224,248,000
Beta: 1.08

Profitability:

Net Margins: 3.19%
Return on Equity: 10.02%
Return on Assets: 6.30%

Debt:

Debt-to-Equity Ratio: 0.41%
Current Ratio: 3.59%
Quick Ratio: 3.09%

Additional Links:

Companies Related to Alexion Pharmaceuticals:

Consensus Ratings for Alexion Pharmaceuticals (NASDAQ:ALXN) (?)

Ratings Breakdown:	1 Sell Rating, 6 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:	Buy (Score: 2.67)
Consensus Price Target:	$180.40 (41.80% upside)

Analysts' Ratings History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Show:

Date	Firm	Action	Rating	Price Target
9/23/2016	Jefferies Group	Lower Price Target	Hold	$140.00 -> $120.00
9/22/2016	Wedbush	Initiated Coverage	Neutral	$132.00
9/22/2016	Cowen and Company	Reiterated Rating	Buy
9/20/2016	Citigroup Inc.	Boost Price Target	Buy	$154.00 -> $155.00
9/15/2016	FBR & Co	Initiated Coverage	Underperform
8/16/2016	Piper Jaffray Cos.	Reiterated Rating	Overweight	$185.00
7/29/2016	Brean Capital	Reiterated Rating	Buy	$221.00
7/29/2016	Barclays PLC	Lower Price Target	Equal Weight	$165.00 -> $150.00
7/29/2016	Stifel Nicolaus	Lower Price Target	Buy	$195.00 -> $182.00
7/17/2016	Leerink Swann	Reiterated Rating	Buy	$200.00
7/13/2016	SunTrust Banks Inc.	Lower Price Target	Buy	$220.00 -> $197.00
7/12/2016	Royal Bank Of Canada	Initiated Coverage	Outperform	$188.00
7/11/2016	Credit Suisse Group AG	Upgrade	Neutral -> Outperform	$186.00 -> $165.00
6/29/2016	Morgan Stanley	Reiterated Rating	Overweight
6/13/2016	Robert W. Baird	Reiterated Rating	Neutral	$145.00
6/6/2016	Bank of America Corp.	Reiterated Rating	Buy
6/7/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Buy	$228.00 -> $221.00
6/7/2016	BMO Capital Markets	Reiterated Rating	Buy	$168.00 -> $160.00
2/22/2016	Goldman Sachs Group Inc.	Lower Price Target		$186.00 -> $168.00
2/4/2016	JPMorgan Chase & Co.	Lower Price Target		$225.00 -> $185.00
1/7/2016	BTIG Research	Downgrade	Buy -> Neutral
10/13/2015	Raymond James Financial Inc.	Reiterated Rating	Strong-Buy	$225.00
8/4/2015	Deutsche Bank AG	Reiterated Rating	Buy	$215.00
6/23/2015	Sanford C. Bernstein	Set Price Target	Buy	$267.00
5/7/2015	Nomura	Upgrade	Neutral -> Buy	$222.00 -> $246.00

(Data available from 9/26/2014 forward)

Earnings History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/27/2016
7/28/2016	Q216	$1.17	$1.13	$743.18 million	$753.00 million	View	Listen
4/28/2016	Q116	$1.13	$1.11	$710.98 million	$701.00 million	View	Listen
2/3/2016	Q415	$1.10	$1.13	$703.42 million	$701.00 million	View	N/A
10/29/2015	Q315	$1.01	$1.16	$668.33 million	$666.60 million	View	Listen
7/30/2015	Q215	$1.39	$1.44	$628.03 million	$636.00 million	View	Listen
4/23/2015	Q115	$1.32	$1.28	$594.40 million	$600.30 million	View	N/A
1/29/2015	Q414	$1.28	$1.30	$589.85 million	$599.00 million	View	Listen
10/23/2014	Q314	$1.16	$1.27	$541.93 million	$555.10 million	View	Listen
7/24/2014	Q214	$1.07	$1.12	$509.54 million	$512.50 million	View	Listen
4/24/2014	Q114	$1.26	$1.53	$560.22 million	$566.60 million	View	Listen
1/30/2014	Q413	$0.83	$0.87	$430.08 million	$441.90 million	View	Listen
10/24/2013	Q313	$0.79	$0.83	$395.10 million	$400.40 million	View	Listen
7/25/2013	Q2 2013	$0.68	$0.73	$364.80 million	$370.10 million	View	Listen
4/25/2013	Q1 2013	$0.61	$0.65	$336.56 million	$338.90 million	View	Listen
2/14/2013	Q4 2012	$0.52	$0.60	$316.49 million	$320.50 million	View	Listen
10/24/2012		$0.47	$0.60			View	N/A
7/25/2012		$0.36	$0.47			View	N/A
4/24/2012		$0.38	$0.45			View	N/A
2/9/2012		$0.33	$0.41			View	N/A
10/20/2011		$0.28	$0.37			View	N/A
7/21/2011		$0.26	$0.29			View	N/A
4/21/2011		$0.51	$0.59			View	N/A
2/10/2011		$0.50	$0.51			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)

Current Year EPS Consensus Estimate: $3.87 EPS
Next Year EPS Consensus Estimate: $5.15 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	$0.91	$0.91	$0.91
Q2 2016	1	$1.07	$1.07	$1.07
Q3 2016	1	$1.17	$1.17	$1.17
Q4 2016	1	$1.28	$1.28	$1.28

(Data provided by Zacks Investment Research)

Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Insider Ownership Percentage: 4.41%
Institutional Ownership Percentage: 96.34%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/13/2016	Carsten Thiel	EVP	Sell	3,225	$128.67	$414,960.75
9/9/2016	Edward Miller	SVP	Sell	367	$128.32	$47,093.44
9/6/2016	Carsten Thiel	EVP	Sell	1,000	$125.94	$125,940.00
9/2/2016	Julie O'neill	EVP	Sell	650	$126.29	$82,088.50
8/30/2016	Clare Carmichael	EVP	Sell	1,000	$127.76	$127,760.00
8/22/2016	Alvin S Parven	Director	Sell	15,000	$136.53	$2,047,950.00
8/15/2016	Alvin S Parven	Director	Sell	700	$135.51	$94,857.00
8/8/2016	Clare Carmichael	EVP	Sell	165	$137.14	$22,628.10
8/8/2016	David Hallal	CEO	Sell	332	$137.14	$45,530.48
8/8/2016	Heidi L Wagner	SVP	Sell	222	$137.14	$30,445.08
8/8/2016	Leonard Bell	Director	Sell	1,010	$137.14	$138,511.40
8/8/2016	Vikas Sinha	CFO	Sell	277	$137.14	$37,987.78
6/13/2016	John B Moriarty	EVP	Sell	918	$135.72	$124,590.96
5/16/2016	Martin Mackay	EVP	Sell	4,097	$139.20	$570,302.40
5/13/2016	Heidi L Wagner	SVP	Sell	53	$138.65	$7,348.45
4/1/2016	David Hallal	CEO	Sell	1,414	$135.88	$192,134.32
2/29/2016	Clare Carmichael	EVP	Sell	1,312	$138.91	$182,249.92
2/29/2016	David Hallal	CEO	Sell	2,014	$138.93	$279,805.02
2/29/2016	Edward Miller	SVP	Sell	329	$138.91	$45,701.39
2/29/2016	Leonard Bell	Director	Sell	3,995	$138.92	$554,985.40
2/29/2016	Vikas Sinha	CFO	Sell	1,122	$138.91	$155,857.02
2/8/2016	David Hallal	CEO	Sell	11,297	$140.50	$1,587,228.50
2/8/2016	Heidi L. Wagner	SVP	Sell	2,108	$140.93	$297,080.44
2/8/2016	Julie O'neill	EVP	Sell	2,858	$141.83	$405,350.14
2/8/2016	Leonard Bell	Director	Sell	15,872	$139.58	$2,215,413.76
2/8/2016	Vikas Sinha	CFO	Sell	6,547	$140.04	$916,841.88
2/5/2016	Edward Miller	SVP	Sell	1,051	$143.02	$150,314.02
12/29/2015	Leonard Bell	Director	Sell	35,000	$190.66	$6,673,100.00
12/17/2015	Leonard Bell	Director	Sell	70,000	$187.69	$13,138,300.00
12/11/2015	Ann M Veneman	Director	Sell	895	$187.48	$167,794.60
12/11/2015	John B. Moriarty	EVP	Sell	943	$182.73	$172,314.39
12/8/2015	Leonard Bell	Director	Sell	70,000	$188.20	$13,174,000.00
12/8/2015	Saqib Islam	EVP	Sell	950	$190.00	$180,500.00
11/25/2015	Leonard Bell	Director	Sell	35,000	$181.89	$6,366,150.00
10/26/2015	Saqib Islam	EVP	Sell	1,558	$168.44	$262,429.52
9/9/2015	Leonard Bell	Director	Sell	1,050	$180.10	$189,105.00
6/18/2015	Leonard Bell	Director	Sell	27,835	$179.63	$5,000,001.05
3/19/2015	Leonard Bell	CEO	Sell	15,952	$188.07	$3,000,092.64
3/2/2015	Julie O'neill	EVP	Sell	11,665	$101.49	$1,183,880.85
3/2/2015	Leonard Bell	CEO	Sell	1,230	$180.34	$221,818.20
2/10/2015	Clare Carmichael	EVP	Sell	1,490	$171.15	$255,013.50
2/10/2015	David Hallal	COO	Sell	1,980	$171.15	$338,877.00
2/10/2015	Leonard Bell	CEO	Sell	5,740	$171.15	$982,401.00
2/10/2015	Vikas Sinha	CFO	Sell	1,985	$171.15	$339,732.75
2/9/2015	Clare Carmichael	EVP	Sell	1,665	$173.75	$289,293.75
2/9/2015	David Hallal	COO	Sell	2,920	$173.93	$507,875.60
2/9/2015	Leonard Bell	CEO	Sell	8,660	$173.98	$1,506,666.80
2/9/2015	Vikas Sinha	CFO	Sell	2,703	$174.18	$470,808.54
2/4/2015	David Hallal	COO	Sell	1,373	$174.18	$239,149.14
2/4/2015	Leonard Bell	CEO	Sell	5,223	$174.29	$910,316.67
2/4/2015	Vikas Sinha	CFO	Sell	1,571	$174.19	$273,652.49
12/18/2014	David Hallal	COO	Sell	5,494	$182.03	$1,000,072.82
12/18/2014	Leonard Bell	CEO	Sell	30,415	$179.73	$5,466,487.95
12/18/2014	Vikas Sinha	CFO	Sell	5,493	$182.08	$1,000,165.44
12/9/2014	Leonard Bell	CEO	Sell	133,320	$198.26	$26,432,023.20
12/4/2014	Clare Carmichael	SVP	Sell	10,000	$196.25	$1,962,500.00
12/4/2014	William R Keller	Director	Sell	5,000	$196.25	$981,250.00
12/3/2014	Vikas Sinha	CFO	Sell	75,000	$198.96	$14,922,000.00
11/3/2014	David Hallal	COO	Sell	30,000	$190.01	$5,700,300.00
11/3/2014	Martin Mackay	EVP	Sell	9,375	$191.52	$1,795,500.00
11/3/2014	Saqib Islam	SVP	Sell	28,125	$190.50	$5,357,812.50
11/3/2014	Vikas Sinha	CFO	Sell	49,307	$192.63	$9,498,007.41
10/27/2014	John B Moriarty	SVP	Sell	10,000	$189.49	$1,894,900.00
10/27/2014	Stephen P Squinto	EVP	Sell	5,910	$188.58	$1,114,507.80
10/6/2014	John B Moriarty	SVP	Sell	10,000	$179.00	$1,790,000.00
10/3/2014	Stephen P Squinto	EVP	Sell	10,025	$172.41	$1,728,410.25
9/26/2014	Leonard Bell	CEO	Sell	60,000	$165.12	$9,907,200.00
9/24/2014	Stephen P Squinto	EVP	Sell	76	$159.50	$12,122.00
9/18/2014	Leonard Bell	CEO	Sell	44,435	$160.60	$7,136,261.00
9/10/2014	Leonard Bell	CEO	Sell	12,199	$165.38	$2,017,470.62
9/8/2014	Leonard Bell	CEO	Sell	197,801	$165.32	$32,700,461.32
8/27/2014	Leonard Bell	CEO	Sell	5,912	$169.17	$1,000,133.04
8/25/2014	Andreas Rummelt	Director	Sell	5,052	$170.53	$861,517.56
8/15/2014	Leonard Bell	CEO	Sell	70,000	$167.99	$11,759,300.00
8/13/2014	Leonard Bell	CEO	Sell	105,000	$160.71	$16,874,550.00
8/12/2014	Leonard Bell	CEO	Sell	80,458	$160.16	$12,886,153.28
8/4/2014	David Hallal	EVP	Sell	1,349	$158.00	$213,142.00
8/4/2014	Leonard Bell	CEO	Sell	5,145	$157.88	$812,292.60
8/4/2014	Vikas Sinha	CFO	Sell	1,525	$157.82	$240,675.50
7/30/2014	Leonard Bell	CEO	Sell	127,289	$162.93	$20,739,196.77
7/29/2014	Leonard Bell	CEO	Sell	1,200	$164.93	$197,916.00
7/28/2014	Leonard Bell	CEO	Sell	105,600	$162.38	$17,147,328.00
6/20/2014	Leonard Bell	CEO	Sell	90,280	$163.60	$14,769,808.00
6/12/2014	Martin Mackay	EVP	Sell	25,000	$166.42	$4,160,500.00
6/5/2014	William R Keller	Director	Sell	3,425	$170.00	$582,250.00
5/27/2014	Leonard Bell	CEO	Sell	70,000	$166.16	$11,631,200.00
5/20/2014	Leonard Bell	CEO	Sell	70,000	$155.96	$10,917,200.00
5/14/2014	Martin Mackay	EVP	Sell	3,574	$160.85	$574,877.90
5/13/2014	Alvin Parven	Director	Sell	12,276	$160.78	$1,973,735.28
4/29/2014	Leonard Bell	CEO	Sell	70,000	$156.20	$10,934,000.00
2/10/2014	Stephen Squinto	EVP	Sell	7,055	$158.04	$1,114,972.20
2/7/2014	David Hallal	EVP	Sell	1,620	$155.57	$252,023.40
2/7/2014	Frank Wright	SVP	Sell	1,098	$155.57	$170,815.86
2/7/2014	Joseph Madri	Director	Sell	30,000	$159.00	$4,770,000.00
2/7/2014	Leonard Bell	CEO	Sell	4,620	$155.56	$718,687.20
2/4/2014	Leonard Bell	CEO	Sell	11,790	$154.50	$1,821,555.00
2/4/2014	Stephen Squinto	EVP	Sell	36,989	$155.12	$5,737,733.68
2/4/2014	Vikas Sinha	CFO	Sell	3,552	$154.47	$548,677.44
1/29/2014	Leonard Bell	CEO	Sell	2,660	$133.81	$355,934.60
1/29/2014	Stephen Squinto	EVP	Sell	1,118	$133.31	$149,040.58
1/22/2014	Leonard Bell	CEO	Sell	156,436	$140.80	$22,026,188.80
1/10/2014	Leonard Bell	CEO	Sell	19,155	$134.98	$2,585,541.90
12/19/2013	Leonard Bell	CEO	Sell	175,000	$126.38	$22,116,500.00
10/28/2013	Stephen P Squinto	EVP	Sell	41,037	$124.06	$5,091,050.22
10/28/2013	Vikas Sinha	CFO	Sell	50,000	$122.97	$6,148,500.00
9/16/2013	Joseph Madri	Director	Sell	30,000	$115.00	$3,450,000.00
9/16/2013	Leonard Bell	CEO	Sell	3,500	$115.00	$402,500.00
9/13/2013	Stephen Squinto	EVP	Sell	1,000	$114.37	$114,370.00
9/4/2013	Leonard Bell	CEO	Sell	1,850	$110.07	$203,629.50
9/3/2013	Leonard Bell	CEO	Sell	33,150	$110.19	$3,652,798.50
8/30/2013	Clare Carmichael	SVP	Sell	1,237	$107.58	$133,076.46
8/16/2013	Leonard Bell	CEO	Sell	140,000	$106.08	$14,851,200.00
8/5/2013	Leonard Bell	CEO	Sell	2,919	$116.87	$341,143.53
8/2/2013	Stephen P Squinto	EVP	Sell	14,125	$115.33	$1,629,036.25
7/30/2013	Leonard Bell	CEO	Sell	212,737	$114.62	$24,383,914.94
7/30/2013	Stephen P Squinto	EVP	Sell	1,120	$110.86	$124,163.20
7/12/2013	David Hallal	EVP	Sell	50,000	$120.00	$6,000,000.00
7/1/2013	Stephen P Squinto	EVP	Sell	44,125	$94.97	$4,190,551.25
5/22/2013	R Douglas Norby	Director	Sell	40,000	$102.77	$4,110,800.00
5/20/2013	William R Keller	Director	Sell	9,770	$103.00	$1,006,310.00
5/14/2013	Leonard Bell	CEO	Sell	31,113	$105.74	$3,289,888.62
5/13/2013	Leonard Bell	CEO	Sell	41,220	$100.85	$4,157,037.00
4/10/2013	Leonard Bell	CEO	Sell	26,700	$100.24	$2,676,408.00
2/4/2013	Leonard Bell	CEO	Sell	11,880	$96.27	$1,143,687.60
2/4/2013	Stephen P Squinto	EVP	Sell	2,572	$95.68	$246,088.96
2/4/2013	Vikas Sinha	CFO	Sell	3,483	$95.81	$333,706.23
1/15/2013	Leonard Bell	CEO	Sell	35,000	$98.58	$3,450,300.00
10/31/2012	Patrice Coissac	SVP	Sell	84,764	$91.16	$7,727,086.24

(Data available from 1/1/2013 forward)

Latest Headlines for Alexion Pharmaceuticals (NASDAQ:ALXN)

Date	Headline
	Alexion Gets U.K. Approval for High-Cost Drug (ALXN) - Investopedia (NASDAQ:ALXN) www.investopedia.com - September 24 at 8:47 AM
	News review of 2 biotech stocks: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 23 at 3:53 PM
	Alexion Employees Volunteer Together in Company’s First Global Day of Service (NASDAQ:ALXN) www.publicnow.com - September 23 at 8:16 AM
	Alexion Pharmaceuticals: Two Steps Forward, One Step Back (NASDAQ:ALXN) blogs.barrons.com - September 22 at 3:25 PM
	UK okays Alexion drug costing up to $2 mln but wants price cut (NASDAQ:ALXN) uk.finance.yahoo.com - September 22 at 9:21 AM
	Commit To Buy Alexion Pharmaceuticals At $85, Earn 6.7% Using ... - Nasdaq (NASDAQ:ALXN) www.nasdaq.com - September 21 at 9:44 AM
	Alexion Pharmaceuticals Takes Over #117 Spot From Zoetis (NASDAQ:ALXN) www.thestreet.com - September 20 at 3:25 PM
	Commit To Buy Alexion Pharmaceuticals At $85, Earn 6.7% Using Options (NASDAQ:ALXN) www.nasdaq.com - September 20 at 3:25 PM
	Trading the Biotech News: Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 19 at 4:22 PM
	HC Stocks in Focus! Raptor Pharmaceutical Corp. (RPTP), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - share market updates (press release) (NASDAQ:ALXN) sharemarketupdates.com - September 19 at 8:11 AM
	Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), a large market cap stock a smart buy? (NASDAQ:ALXN) twincountynews.com - September 17 at 3:28 PM
	Stocks Charging Up for Historic Highs: Mylan N.V. (NASDAQ:MYL), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Street Wise Report (press release) (blog) (NASDAQ:ALXN) streetwisereport.com - September 16 at 3:28 PM
	Alexion Pharmaceuticals, Inc. 35.4% Potential Decrease Now Implied by FBR & Co. - DirectorsTalk Interviews (NASDAQ:ALXN) www.directorstalkinterviews.com - September 16 at 3:28 PM
	FBR Capital Starts Coverage on Alexion Pharmaceuticals, Inc. (ALXN) With An Initial Rating Of “Underperform” (NASDAQ:ALXN) www.fidaily.com - September 16 at 12:08 PM
	Alexion's 'Uncommon Strength' Campaign Offers a Win-Win (ALXN) - Investopedia (NASDAQ:ALXN) www.investopedia.com - September 15 at 12:19 PM
	Coverage initiated on Alexion Pharma by FBR & Co. (NASDAQ:ALXN) finance.yahoo.com - September 15 at 12:19 PM
	Alexion’s ‘Uncommon Strength’ Campaign Offers a Win-Win (ALXN) (NASDAQ:ALXN) www.investopedia.com - September 14 at 8:42 PM
	What is the Sell-side Saying About Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)? - Frisco Fastball (NASDAQ:ALXN) friscofastball.com - September 14 at 3:26 PM
	Alexion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALXN) : September 14, 2016 (NASDAQ:ALXN) www.capitalcube.com - September 14 at 3:26 PM
	Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases (NASDAQ:ALXN) www.publicnow.com - September 14 at 8:58 AM
	(NASDAQ:ALXN) 2 Stocks Analyst-Opinion Need Close Attention Mylan NV (NASDAQ:MYL), Alexion Pharmaceuticals ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 13 at 8:18 AM
	News review of 2 biotech stocks: Cytokinetics, Incorporated (NASDAQ:CYTK), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 13 at 8:18 AM
	Stock Valuation Recap for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Post News (NASDAQ:ALXN) www.kentuckypostnews.com - September 10 at 8:13 AM
	Market Review: Watching Session Activity of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares - Post News (NASDAQ:ALXN) www.kentuckypostnews.com - September 9 at 3:26 PM
	Analysts Valuations For Two Stocks: Chipotle Mexican Grill, Inc. (NYSE:CMG), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 6 at 8:33 PM
	Alexion to Present at Upcoming Investor Conferences (NASDAQ:ALXN) www.publicnow.com - September 6 at 3:25 PM
	Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expects Sales Of $7098.44 - Investor Newswire (NASDAQ:ALXN) www.investornewswire.com - September 5 at 3:27 PM
	Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) To Report September 2016 Results - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 5 at 3:27 PM
	ETF’s with exposure to Alexion Pharmaceuticals, Inc. : September 2, 2016 (NASDAQ:ALXN) www.capitalcube.com - September 2 at 3:28 PM
	Analysts Valuations For Two Stocks: Energy Transfer Equity LP (NYSE:ETE), Alexion Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - September 1 at 3:28 PM
	A look at a High Market Cap Stock: Alexion Pharmaceuticals, Inc., ALXN - The Daily Leicester (NASDAQ:ALXN) thedailyleicester.com - September 1 at 3:28 PM
	Biotech Stocks: Look At Those Takeover Premiums! (NASDAQ:ALXN) blogs.barrons.com - September 1 at 3:28 PM
	Shares Slipping Lower Over the Past Month: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Post News (NASDAQ:ALXN) www.kentuckypostnews.com - September 1 at 11:53 AM
	Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : September 1, 2016 (NASDAQ:ALXN) www.capitalcube.com - September 1 at 11:53 AM
	5 Growth Stocks to Buy in September (NASDAQ:ALXN) www.fool.com - August 31 at 3:25 PM
	Stock in Limelight: Market Weighs in on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Post News (NASDAQ:ALXN) www.kentuckypostnews.com - August 30 at 11:37 AM
	Alexion Pharma's (ALXN) ALXN1007 Granted EC Orphan Drug Designation as GVHD Treatment - StreetInsider.com (NASDAQ:ALXN) www.streetinsider.com - August 30 at 11:37 AM
	Alexion's GVHD Candidate Gets Orphan Drug Status in the EU (NASDAQ:ALXN) finance.yahoo.com - August 30 at 11:37 AM
	European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (... (NASDAQ:ALXN) ih.advfn.com - August 29 at 9:07 PM
	Alexion Pharma's (ALXN) ALXN1007 Granted EC Orphan Drug Designation as GVHD Treatment (NASDAQ:ALXN) www.streetinsider.com - August 29 at 9:07 PM
	4:34 pm Alexion Pharma announces European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (NASDAQ:ALXN) finance.yahoo.com - August 29 at 9:07 PM
	European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD) (NASDAQ:ALXN) www.publicnow.com - August 29 at 9:07 PM
	Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expects To Hit Sales Of $7098.44 - Investor Newswire (NASDAQ:ALXN) www.investornewswire.com - August 29 at 4:05 PM
	Biotech Stocks Worth a Closer Look: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Achillion Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - August 29 at 4:05 PM
	Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd (NASDAQ:ALXN) finance.yahoo.com - August 27 at 8:14 AM
	Analysts Valuations For Two Stocks: Alexion Pharmaceuticals (NASDAQ:ALXN), Kimco Realty Corp (NYSE:KIM) - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - August 26 at 3:26 PM
	How Much Did BioMarin’s Lead Drug Vimizim Earn in 1H16? (NASDAQ:ALXN) marketrealist.com - August 26 at 11:36 AM
	What Do Analysts Think about BioMarin’s Return Potential? (NASDAQ:ALXN) marketrealist.com - August 26 at 11:36 AM
	Analysts Valuations For Two Stocks: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Allergan plc Ordinary Shares ... - The Voice Registrar (NASDAQ:ALXN) voiceregistrar.com - August 25 at 3:29 PM
	Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from Biotechnology – Todays Top Gains (NASDAQ:ALXN) twincountynews.com - August 25 at 8:13 AM